TC Biopharm (Holdings) PLC announced that it has received MHRA and Research Ethics Committee approvals to initiate gamma-delta T cell therapy clinical trials of OmnImmune® for the treatment of Acute Myeloid Leukemia (AML). OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for…
eTurboNews nkhani ndi za olembetsa okha. Kulembetsa ndi FREE.
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
ZOMWE MUNGACHITE PA NKHANIYI:
- TC Biopharm (Holdings) PLC yalengeza kuti yalandira zivomerezo za MHRA ndi Research Ethics Committee kuti ayambitse kuyesa kwa gamma-delta T cell therapy ya OmnImmune® pochiza Acute Myeloid Leukemia (AML).
- OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells has already received orphan drug designation for….
- eTurboNews nkhani ndi za olembetsa okha.
